Cardax Pharmaceuticals
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cardax Pharmaceuticals - overview
Established
2006
Location
Honolulu, HI, US
Primary Industry
Pharmaceuticals
About
Cardax Pharmaceuticals is focused on developing and marketing health supplements, particularly its flagship astaxanthin product, ZanthoSyn®, which is aimed at enhancing inflammatory health and oxidative stress management. Founded in 2006 and headquartered in Honolulu, US, Cardax Pharmaceuticals specializes in dietary supplements and pre-clinical pharmaceutical candidates. The company has raised a total of USD 0. 5 mn in funding through a PIPE deal in June 2015.
David Watumull leads the firm as CEO. Cardax, Inc. primarily markets its flagship product, ZanthoSyn®, an astaxanthin dietary supplement that promotes inflammatory health. The supplement is available directly to consumers via its commercial website, www.
zanthosyn. com. Additionally, the company has developed pre-clinical pharmaceutical candidates, CDX-101 for cardiovascular inflammation and CDX-301 for macular degeneration, further reflecting its previous focus on pharmaceutical development. In 2020, Cardax, Inc.
reported a revenue of USD 538,946. The company operates through direct-to-consumer sales of ZanthoSyn®, with plans to diversify its revenue streams potentially through licensing or sales of its pre-clinical products. Cardax plans to leverage its most recent funding of USD 0. 5 mn from the PIPE deal in June 2015 to support the expansion of its product line and explore new markets.
The firm is targeting international markets for ZanthoSyn® to increase its consumer base. Further details on new product launches or specific release dates were not disclosed.
Current Investors
Advantage Capital
Primary Industry
Pharmaceuticals
Sub Industries
Drug Stores/Convenience Stores, Pharmaceutical Research & Development
Website
www.cardaxpharma.com
Total Amount Raised
Subscriber access only
Cardax Pharmaceuticals - financials
| Fiscal Year Ended | Mar 31, 2013 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 75,354 | - | - | - | 35,258 | 610,323 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | 1631.0% | - | - | - |
| EBITDA (USD) | (65,132) | (3,494,933) | (16,838,399) | (4,377,342) | (1,801,123) | (1,972,848) | - | - | - |
| Operating Income (USD) | (65,156) | (3,591,745) | (16,881,963) | (4,401,100) | (1,830,224) | (2,002,270) | - | - | - |
| Operating Margin | (86.5%) | - | - | - | (5190.9%) | (328.1%) | - | - | - |
| % EBITDA Margin | (86.4%) | - | - | - | (5108.4%) | (323.2%) | - | - | - |
| NET Income (USD) | (65,156) | (4,361,165) | (16,994,625) | (4,257,875) | (1,783,705) | (1,985,234) | - | - | - |
| % Net Margin | (86.5%) | - | - | - | (5059.0%) | (325.3%) | - | - | - |
Cardax Pharmaceuticals - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Buyout | Completed | Cardax Pharmaceuticals | - |
Displaying 1 - 1 of 1
Cardax Pharmaceuticals - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.